<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: INMARKTM now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients	</title>
	<atom:link href="https://www.novumpr.nl/2016/06/30/inmarktm-now-enrolling-first-study-to-evaluate-the-effect-of-ofev-nintedanib-on-biomarkers-reflecting-the-underlying-fibrotic-process-in-ipf-patients/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2016/06/30/inmarktm-now-enrolling-first-study-to-evaluate-the-effect-of-ofev-nintedanib-on-biomarkers-reflecting-the-underlying-fibrotic-process-in-ipf-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=inmarktm-now-enrolling-first-study-to-evaluate-the-effect-of-ofev-nintedanib-on-biomarkers-reflecting-the-underlying-fibrotic-process-in-ipf-patients</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Thu, 30 Jun 2016 08:55:04 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
